Loading
Immunotherapy and Immune Responses / Vaccines and Immunoinformatics Approaches · Journal article
Experimental & Molecular Medicine · August 13, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes the current state of personalized cancer vaccine (PCV) development and proposes a five-dimensional framework—termed 'Take Five'—to guide future advancement across neoantigen prediction, manufacturing speed, therapeutic efficacy, cost-effectiveness, and regulatory pathways. It does not report original empirical findings or clinical trial outcomes, but rather provides a conceptual roadmap for translating PCV research into clinical practice.
Narrative review. Patients with cancer eligible for personalized cancer vaccine approaches; focus is on immunological and tumor genetic heterogeneity..
mRNA-lipid nanoparticle platforms offer advantages of rapid manufacturing, potent antigen expression, and integration with immunostimulatory cytokines PCVs achieve tumor-specific immunity through identification of patient-derived neoantigens Five interconnected dimensions are proposed as essential for PCV maturation: neoantigen prediction, rapid delivery, combination therapy efficacy, cost-effective manufacturing, and regulatory innovation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should use this framework to understand the current landscape of PCV development and the key barriers to clinical translation. The 'Take Five' model may guide prioritization of research and implementation efforts toward balanced advancement across multiple dimensions.
A narrative review synthesizing current evidence on personalized cancer vaccine development, proposing a framework for future optimization rather than reporting original empirical findings.
As stated by the source record.
Clinicians and researchers should use this framework to understand the current landscape of PCV development and the key barriers to clinical translation. The 'Take Five' model may guide prioritization of research and implementation efforts toward balanced advancement across multiple dimensions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Precision medicine provides a therapeutic framework that addresses the interindividual diversity in tumor genetics, immunological determinants of disease, and immune responsiveness. Among precision approaches, personalized cancer vaccines (PCVs) have gained attention as a promising strategy for inducing tumor-specific immunity by identifying patient-derived neoantigens. Despite encouraging clinical outcomes, the development of PCVs faces major challenges in optimizing antigen selection, delivery, immune activation, and clinical translation. This Review summarizes current advances in PCV research, covering tumor antigen classification, neoantigen prediction algorithms, and the evolution of delivery technologies such as peptide, dendritic cell, DNA, and mRNA-lipid nanoparticle platforms. We highlight the advantages of mRNA-lipid nanoparticle systems that enable rapid manufacturing, potent antigen expression, and integration with immunostimulatory cytokines. Furthermore, we discuss emerging combination strategies involving cytokine engineering and T cell modulation that provide new opportunities to enhance immunogenicity and therapeutic efficacy. Ultimately, we propose that the future maturation of PCVs will require a coordinated process across five interconnected dimensions: (1) advances in neoantigen prediction technologies, (2) rapid delivery of PCVs to patients, (3) an increase in anticancer efficacy through combination therapy strategies, (4) establishment of cost-effective manufacturing processes, and (5) regulatory innovation. In this Review, we conceptualize this multidimensional alignment as “Take Five,” a unifying framework to bring precision, rhythm, and balance to next-generation cancer immunotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.